Glyxambi

Indicated For

type 2 diabetes

About This Medication

# Boehringer Cares Patient Assistance Program Patient Guide: How to Get Glyxambi at Low or No Cost Glyxambi (empagliflozin/linagliptin) is a prescription medication used to manage **type 2 diabetes** in adults, helping to control blood sugar levels when diet and exercise alone are not enough. The **Boehringer Cares Patient Assistance Program** from Boehringer Ingelheim offers this and other eligible medications **free of charge** to qualifying US patients who are uninsured or underinsured and meet income guidelines. ## About Glyxambi Glyxambi combines two active ingredients: **empagliflozin**, an SGLT2 inhibitor that helps the kidneys remove excess sugar from the blood through urine, and **linagliptin**, a DPP-4 inhibitor that increases insulin production and decreases sugar production in the liver. It's typically taken once daily with or without food and is not for type 1 diabetes or diabetic ketoacidosis. Common side effects include urinary tract infections, yeast infections, and dehydration risks—always consult your doctor for personalized advice. This program ensures eligible patients can access Glyxambi without cost barriers, supporting better diabetes management and reducing complications like heart disease or kidney issues.[3][4][6] ## Who Qualifies? To qualify for the Boehringer Cares Patient Assistance Program, you must meet these key criteria: - Be a **resident of the United States or US Territories** (including Puerto Rico) with a physical address for delivery. - Be **uninsured or underinsured**, meaning no health coverage or coverage insufficient to obtain Glyxambi. - Have **no access to other sources** of coverage or funding for the medication. - Meet **household income guidelines** set by the program (specific Federal Poverty Level (FPL) percentages are not publicly detailed but are needs-based; proof of income may be required). - Have a **valid prescription** from a US-licensed healthcare provider. Certain Medicare Part D patients may qualify if they face high drug costs, lack other assistance, and have no additional prescription coverage—attach a Medicare Low Income Subsidy denial letter if applicable. The program reviews all applications against these eligibility rules.[3][4][6][7] ## Income Eligibility Breakdown Exact income thresholds (e.g., % of FPL) are not specified in program details and vary by household size—contact the program for your situation. Applications require income verification, such as tax returns, pay stubs, or benefit statements. Here's a general overview based on typical patient assistance structures (confirm with program): | Household Size | Estimated Max Income (as % FPL)* | Notes | |---------------|---------------------------------|-------| | 1 (Individual) | ~400-500% FPL | Proof required; exact % not listed | | 2 (Couple) | ~400-500% FPL | Household income combined | | 3 | ~400-500% FPL | Includes dependents | | 4+ | ~400-500% FPL | Add ~$5,000 per additional person | *Estimates; program uses specific guidelines. Uninsured/underinsured status is primary. Call 1-800-556-8317 for precise thresholds.[4][5][6] ## Insurance Requirements The program targets those with **limited or no coverage**: - **Uninsured**: No health insurance at all. - **Underinsured**: Insurance doesn't cover Glyxambi fully (e.g., high copays/deductibles). - **Medicare/Medicaid**: Some Part D enrollees qualify if costs are unaffordable and no Extra Help/LIS available (provide denial proof). No dual coverage with other drug funding sources allowed. Commercially insured patients generally don't qualify unless coverage is inadequate. The healthcare provider confirms this in the application.[4][6][7] ## Step-by-Step Application Process Applying is straightforward with multiple methods. Your doctor plays a key role. 1. **Get a Prescription**: Ask your healthcare provider (HCP) to confirm Glyxambi is appropriate and complete program forms. 2. **Download/Request Forms**: Visit Boehringer Ingelheim's site for the application (English/Spanish available). Or call 1-800-556-8317 (Mon-Fri, 8:30 AM-6:00 PM ET).[2][7] 3. **Complete Sections**: - **Patient Sections (1-4)**: Personal info, income, insurance details, signature. - **HCP Sections (5-6)**: Prescription, medical confirmation, original signature.[4] 4. **Gather Documents**: Proof of income (e.g., 2025 tax return, W-2s, SSI statements), insurance cards/denial letters, ID. 5. **Submit**: - **Fax**: 1-866-851-2827 (preferred for speed). - **Mail**: Boehringer Cares Patient Assistance Program, PO Box 99055, Jeffersontown, KY 40296. - Follow form instructions exactly.[1][4][6] 6. **Track Status**: Call the program after submission. Help from services like Simplefill can simplify this— they handle applications for you.[8] ## Timeline and Delivery Processing time varies (typically 2-4 weeks, but not specified—call for updates). Once approved, Glyxambi ships **directly to your home address** free of charge, usually a 3-12 month supply depending on eligibility. **Reauthorization is required** annually or upon changes (e.g., income/insurance); resubmit forms before supply ends to avoid gaps.[3][4][6] ## Alternatives if Denied or Ineligible - **Reapply**: Fix issues (e.g., update docs) and resubmit. - **Other Programs**: Check NeedyMeds, RxAssist, or PAN Foundation for diabetes meds. Simplefill matches you to alternatives.[7][8] - **Manufacturer Coupons/Savings Cards**: For commercially insured (not via this PAP). - **State Assistance**: Medicaid expansion or local diabetes programs. - **Generic Options**: Discuss empagliflozin or linagliptin separately with your doctor. No biosimilars for Glyxambi listed.[6] ## Refill Process Approved patients get periodic shipments. About 30 days before running out, your HCP or you request reauthorization via new forms. Program notifies of approval/denial.[4] ## Important Disclaimer This guide is for informational purposes only and based on available program details as of 2026. Eligibility, terms, and meds can change—always verify with Boehringer Cares at 1-800-556-8317 or their site. Not medical/financial advice; consult your doctor and advisor. Boehringer Ingelheim reserves rights to modify/terminate the program. Glyxambi use requires physician oversight.

Program information last verified: March 30, 2026